SANSERT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Feb 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANSERT is an oral small-molecule tablet approved in 1962 by Novartis with unknown mechanism of action and indication. The product's specific therapeutic use and pharmacologic class require external verification given the incomplete data profile.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial teams likely focused on managed decline and lifecycle extension strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect SANSERT's mature, LOE-approaching status with minimal hiring momentum. Career progression on this product is constrained; professionals should expect focus on defensive strategies and portfolio transition planning.
Brand ManagerField Sales Representative
Worked on SANSERT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.